Sorrento therapeutics

Beleggen in aandelen beurs New York, Dow Jones, Nasdaq-100 en S&P500

believer
Forum elite
Forum elite
Berichten: 4930
Lid geworden op: 14 jan 2015 17:30
waarderingen: 4303
Contacteer:

Re: Sorrento therapeutics

Bericht door believer »








Volg Beursig.com op Twitter en Facebook


ancaoli
Forum veteraan
Forum veteraan
Berichten: 1707
Lid geworden op: 28 jan 2018 18:54
waarderingen: 894
Contacteer:

Re: Sorrento therapeutics

Bericht door ancaoli »

Interessante post over Sorrento financing. Lees vooral de printscreen.

https://stocktwits.com/wjgesq/message/249549307
Vaste Portefeuille:Recticel, WRN, Accentis, Global G, Roularta, Argenx, Agfa, Ontex, OCI, Sorrento, Inventiva

Stefkamielkafkajr
Forum actieveling
Forum actieveling
Berichten: 782
Lid geworden op: 25 dec 2013 21:48
waarderingen: 253
Contacteer:

Re: Sorrento therapeutics

Bericht door Stefkamielkafkajr »

Sorrento COVID-19 R&D 13 oktober 2020 Details pijplijnoproep vrijgegeven
GEPUBLICEERD
9 OKT.2020 19:46 EDT
SAN DIEGO , 9 oktober 2020 (GLOBE NEWSWIRE) - Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") heeft vandaag details vrijgegeven over de aanstaande COVID-19 Pipeline Update-oproep en webcast op 13 oktober 2020.

T itel : Sorrento Therapeutics COVID-19 Pipeline Update, R&D Discussion and Management Q&A Conference ID: 2066037 Datum van oproep: 10/13/2020 Tijd van oproep: 16:30 Eastern Time Verwachte duur: 60 minuten + vragen (analisten en algemeen publiek )

Voor geregistreerde analisten en vooraf gecertificeerde deelnemers:

Gratis nummer : (833) 665-0715

Voor andere deelnemers (webcast, met mogelijkheid om vragen in te dienen tijdens de sessie):

https://edge.media-server.com/mmc/p/tun863t9

Managementdeelnemers zijn onder meer: Dr. Henry Ji , voorzitter en CEODr. Mark Brunswick , SVP en hoofd Regelgeving en kwaliteit Dr. Robert Allen , SVP, ontwikkeling van antivirale en oncolytische immunotherapie Dr. Mike Royal , Chief Medical Officer Dr. Alexis Nahama , SVP Corporate Development

O & O- dagagenda:

• Strategic Outlook (dr . Henry Ji )

• Therapeutische pijplijn - klinische fase (beheer)

STI-1499 (neutraliserend antilichaam)
STI-5656 (abivertinib)
• Therapeutische pijplijn - IND die fase (management) mogelijk maakt

STI-2020 (affiniteitsgerijpte STI-1499)
STI-2099 (gecodeerd plasmide-DNA dat STI-2020 tot expressie brengt)
• Therapeutische Discovery (dr . Henry Ji )

Cocktail met neutraliserende antilichamen (COVI-SHIELD ™)
Bispecifieke neutraliserende antilichamen
STI-2030 (Salicyn-30)
STI-4398 (COVIDTRAP ™: ACE2 receptor decoy proteïne)
STI-3333 (T-VIVA-19 ™: vaccin op eiwitbasis)
I-Cell-platform voor het afleveren van vaccins
• Diagnostiek (beheer)

COVI-TRACK ™: IgG / IgM-antilichaamtest
COVI-TRACE ™: HP-LAMP moleculaire detectietest
COVI-STIX ™: virale antigeentest
De webcast zal gedurende 30 dagen beschikbaar zijn op de website van Sorrento Therapeutics op www.sorrentotherapeutics.com .

Over Sorrento Therapeutics, Inc. Sorrento is een biofarmaceutisch bedrijf dat op antilichamen is gericht in de klinische fase en nieuwe therapieën ontwikkelt voor de behandeling van kanker en COVID-19. Sorrento's multimodale, meervoudige aanpak van kankerbestrijding wordt mogelijk gemaakt door zijn uitgebreide immuno-oncologieplatforms, waaronder belangrijke activa zoals volledig menselijke antilichamen ("G-MAB ™ -bibliotheek"), immunocellulaire therapieën in de klinische fase ("CAR-T", "DAR-T"), antilichaam-geneesmiddelconjugaten ("ADC's") en oncolytisch virus in het klinische stadium ("Seprehvir®", "Seprehvec ™"). Sorrento ontwikkelt ook potentiële antivirale therapieën en vaccins tegen coronavirussen, waaronder COVIDTRAP ™, ACE-MAB ™, COVI-MAB ™, COVI-GUARD ™, COVI-SHIELD ™, COVI-AMG ™ en T-VIVA-19 ™; en diagnostische testoplossingen, waaronder COVI-TRACK ™,

Sorrento's toewijding aan levensverbeterende therapieën voor patiënten wordt ook aangetoond door onze inspanningen om een ​​eersteklas (TRPV1-agonist) niet-opioïde pijnbestrijding klein molecuul, resiniferatoxine ("RTX") en ZTlido® (topisch lidocaïne-systeem) te bevorderen 1,8% voor de behandeling van postherpetische neuralgie. RTX heeft een fase 1B-studie afgerond voor hardnekkige pijn geassocieerd met kanker en een fase 1B-studie bij artrosepatiënten. ZTlido® is op 28 februari 2018 goedgekeurd door de FDA .

Bezoek voor meer informatie www.sorrentotherapeutics.com

Toekomstgerichte verklaringen Dit persbericht en alle verklaringen die voor en tijdens een presentatie of vergadering zijn gedaan, bevatten toekomstgerichte verklaringen met betrekking tot Sorrento Therapeutics, Inc., onder de veiligehavenbepalingen van sectie 21E van de Private Securities Litigation Reform Act van 1995 en onderhevig aan risico's en onzekerheden die ertoe zouden kunnen leiden dat de werkelijke resultaten wezenlijk verschillen van de verwachte resultaten. Toekomstgerichte verklaringen omvatten verklaringen over de pijplijn en plannen van Sorrento met betrekking tot de strategische vooruitzichten en klinische en preklinische COVID-19-programma's, de COVID-19-kandidaten voor therapeutische en diagnostische producten en de pijplijn, en de eigen technologieplatforms. Risico's en onzekerheden die ertoe kunnen leiden dat onze werkelijke resultaten wezenlijk en nadelig verschillen van die uitgedrukt in onze toekomstgerichte verklaringen, omvatten, maar zijn niet beperkt tot: risico's met betrekking tot de technologieën en vooruitzichten van Sorrento en haar dochterondernemingen, gelieerde ondernemingen en partners, en samenwerkingen, waaronder, maar niet beperkt tot klinische ontwikkelingsrisico's, inclusief risico's in de voortgang, timing, kosten en resultaten van klinische onderzoeken en productontwikkelingsprogramma's; risico van moeilijkheden of vertragingen bij het verkrijgen van wettelijke goedkeuringen; het risico bestaat dat de resultaten van klinische onderzoeken niet voldoen aan een of alle eindpunten van een klinische studie en dat de gegevens die uit dergelijke onderzoeken worden gegenereerd, mogelijk geen wettelijke indiening of goedkeuring ondersteunen; risico's dat eerdere test-, studie- en proefresultaten mogelijk niet worden gerepliceerd in toekomstige studies en proeven; risico's van het vervaardigen en leveren van geneesmiddelen; risico's in verband met het gebruik van de expertise van zijn werknemers, dochterondernemingen, gelieerde ondernemingen en partners om het bedrijf bij te staan ​​bij de uitvoering van de strategieën van zijn kandidaat-therapeutische en diagnostische producten; risico's gerelateerd aan de wereldwijde impact van COVID-19;Securities and Exchange Commission , inclusief Sorrento's jaarverslag op formulier 10-K voor het jaar dat eindigde op 31 december 2019 , en daaropvolgende kwartaalrapporten op formulier 10-Q die zijn ingediend bij de Securities and Exchange Commission , inclusief de risicofactoren die in die indieningen zijn uiteengezet. Beleggers worden gewaarschuwd om niet overmatig te vertrouwen op deze toekomstgerichte verklaringen, die alleen gelden vanaf de datum van dit persbericht, en wij zijn niet verplicht om enige toekomstgerichte verklaring in dit persbericht bij te werken, behalve zoals vereist door de wet.

Neem contact op met Alexis Nahama , DVM (SVP Corporate Development) E-mail: mediarelations@sorrentotherapeutics.com

Sorrento® en het Sorrento-logo zijn geregistreerde handelsmerken van Sorrento Therapeutics, Inc. G-MAB ™, COVI-GUARD ™, COVI-SHIELD ™, COVI-AMG ™, COVIDTRAP ™, T-VIVA-19 ™, COVI-MAB ™, ACE-MAB ™, COVI-TRACK ™, COVI-STIX ™ en COVI-TRACE ™ zijn handelsmerken van Sorrento Therapeutics, Inc.

ZTlido® is een handelsmerk dat eigendom is van Scilex Pharmaceuticals Inc. Alle andere handelsmerken zijn eigendom van hun respectievelijke eigenaren. © 2020 Sorrento Therapeutics, Inc. Alle rechten voorbehouden.

15-SORRENTO-Therapeutics-Logo-FINAL.png

Sorrento Therapeutics, Inc.

IN DIT VERHAAL
SRNE
alwaysright liked last!
Altice europe,aegon,, euronav, acacia pharma,fagron,,, greenyard ,pharming, , econocom.Xfab.oxurion.sorrento therapeutics.luckin coffe adr

alwaysright
Forum actieveling
Forum actieveling
Berichten: 921
Lid geworden op: 10 mei 2013 19:25
waarderingen: 362
Contacteer:

Re: Sorrento therapeutics

Bericht door alwaysright »

Ik ben erg benieuwd wat ze te melden hebben...dus half twaalf s-nachts.

Gebruikersavatar
Naz-T
Forum veteraan
Forum veteraan
Berichten: 1085
Lid geworden op: 06 sep 2018 20:48
waarderingen: 463
Contacteer:

Re: Sorrento therapeutics

Bericht door Naz-T »

Is after hour trading dan ook al gesloten?

alwaysright
Forum actieveling
Forum actieveling
Berichten: 921
Lid geworden op: 10 mei 2013 19:25
waarderingen: 362
Contacteer:

Re: Sorrento therapeutics

Bericht door alwaysright »

Foutje....die conferentie begint om 22.30.
Dat gedoe met zomer en wintertijd :D

sepan
Forum veteraan
Forum veteraan
Berichten: 1544
Lid geworden op: 08 aug 2012 08:08
waarderingen: 711
Contacteer:

Re: Sorrento therapeutics

Bericht door sepan »

believer liked last!

ancaoli
Forum veteraan
Forum veteraan
Berichten: 1707
Lid geworden op: 28 jan 2018 18:54
waarderingen: 894
Contacteer:

Re: Sorrento therapeutics

Bericht door ancaoli »

Interessant...

Sorrento's 1499 is listed in regeneron's patent

http://www.uspto.report/patent/grant/1078

In some embodiments of the method for treating or preventing infection with a coronavirus, the subject is administered one or more further therapeutic agents. In some cases, the one or more further therapeutic agents is an anti-viral drug or a vaccine. In some cases, the one or more further therapeutic agents is selected from the group consisting of: an anti-inflammatory agent, an antimalarial agent, an antibody or antigen-binding fragment thereof that specifically binds TMPRSS2, and an antibody or antigen-binding fragment thereof that specifically binds to CoV-S. In some cases, the antimalarial agent is chloroquine or hydroxychloroquine. In some cases, the anti-inflammatory agent is an antibody, such as for example, sarilumab, tocilizumab, or gimsilumab. In some embodiments, the further therapeutic agent is a second antibody or antigen-binding fragment comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 sequences of Table 4. Other antibodies that can be used alone or in combination with one another or with one or more of the antibodies disclosed herein for use in the context of the methods of the present disclosure include, e.g., LY-CoV555 (Eli Lilly); 47D11 (Wang et al Nature Communications Article No. 2251); B38, H4, B5 and/or H2 (Wu et al., 10.1126/science.abc2241 (2020); STI-1499 (Sorrento Therapeutics); VIR-7831 and VIR-7832 (Vir Biotherapeutics).
MONEYCAT liked last!
Vaste Portefeuille:Recticel, WRN, Accentis, Global G, Roularta, Argenx, Agfa, Ontex, OCI, Sorrento, Inventiva

believer
Forum elite
Forum elite
Berichten: 4930
Lid geworden op: 14 jan 2015 17:30
waarderingen: 4303
Contacteer:

Re: Sorrento therapeutics

Bericht door believer »


believer
Forum elite
Forum elite
Berichten: 4930
Lid geworden op: 14 jan 2015 17:30
waarderingen: 4303
Contacteer:

Re: Sorrento therapeutics

Bericht door believer »

News Release
Sorrento Adds Mesenchymal Stem Cell Program (MSC) That Has Been Cleared for a Phase 1 Trial by the FDA to the Pipeline of COVID-19 Focused Rescue Therapies

October 12, 2020 at 5:21 PM EDT
Download PDF
SAN DIEGO, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has entered into an exclusive license agreement with Personalized Stem Cells, Inc. (PSC) to acquire global rights to its adipose derived mesenchymal stem cells (MSCs) for patients suffering from acute respiratory distress syndrome (ARDS) associated with COVID-19, which have been cleared for a Phase 1 clinical trial by the FDA.

The study is a single arm, non-randomized Phase 1 study of the safety and preliminary efficacy of an adipose-derived allogeneic MSC product candidate. The outcome data will be compared to contemporaneous non-enrolled patients at the same clinical site(s) as the enrolled patients. The primary objective is to evaluate the safety of intravenous infusion of allogeneic adipose stem cells in patients with COVID-19 and in respiratory distress. The secondary objective is to evaluate a set of safety and efficacy outcome variables to give guidance regarding the risk/benefit ratio in patients with COVID-19 respiratory distress.

More information on the Phase 1 trial can be found at:

https://clinicaltrials.gov/ct2/show/NCT ... w=2&rank=1

Sorrento will be assuming responsibility for executing the Phase 1 trial, which is targeted to enroll about 20 hospitalized COVID-19 patients in California. Pending the results of the Phase 1 trial, Sorrento expects to expand into Phase 2 trials in multiple relevant geographies as may be determined in consultation with applicable regulatory authorities.

Stem cells have been demonstrated to support resolution of symptoms in multiple disease settings and have the potential to reduce the long-term effects associated with pulmonary tissue damage for these patients. More information on the potential use and benefits of MSCs for patients with COVID-19 can be found in the recently published review at:

https://translational-medicine.biomedce ... 20-02380-2

Stem cells represent a treatment modality with high potential to help in the fight against COVID-19 as a stand-alone therapy or in synergy with other product candidates in Sorrento’s pipeline, including small molecules (abivertinib or salicyn-30) and neutralizing antibodies (STI-1499 or STI 2020).

Until a time where early treatments are more readily available, it is important to provide patients severely afflicted with COVID-19 multimodal solutions that can help increase survival, reduce the time spent in the hospital and reduce long-term sequelae. The long-term lingering effects of COVID-19 on the body can persist for months after patients leave the hospital, especially for patients that received ventilator support. Shortness of breath, difficulty doing simple tasks and pulmonary fibrosis are among the common complaints of long-term effects of the disease on COVID-19 patients leaving the ICU.

Dr. Robert Harman, CEO of PSC stated, “We are delighted to be working with a company such as Sorrento, that has the vision and expertise to take our program through the next steps in the clinical development process. Sorrento saw the translational value of our decades of work in animal health and has acknowledged the extensive manufacturing and regulatory work we have done in bringing human cell lines to a Phase 1 FDA clearance. We are looking forward to collaborating on this initiative and beyond.”

Dr. Henry Ji, Chairman and CEO of Sorrento stated, “Stem cells were a missing piece in our comprehensive portfolio of potential solutions against COVID-19. We now cover multiple stages of the continuum of care from prevention to potential therapeutic solutions for the most advanced stages of the disease. With PSC’s Phase 1 product candidate, we hope to move quickly through the next clinical trials, and, if successful, be able to provide a supportive therapy that may save the lives of the most advanced patients and may also ensure patients who have to undergo intensive care can benefit from a therapy with the potential to minimize the long-term effects of the disease due to the lung damage created by the virus early in the infection.”

About Sorrento Therapeutics, Inc.

Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19. Sorrento’s multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), clinical stage immuno-cellular therapies (“CAR-T”, “DAR-T™”), antibody-drug conjugates (“ADCs”), and clinical stage oncolytic virus (“Seprehvir™”, “Seprehvec™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIDTRAP™, ACE-MAB™, COVI-MAB™, COVI-GUARD™, COVI-SHIELD™, COVI-AMG™ and T-VIVA-19™; and diagnostic test solutions, including COVI-TRACK™, COVI-STIX™ and COVI-TRACE™.

Sorrento’s commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients. ZTlido® was approved by the FDA on February 28, 2018.

For more information visit www.sorrentotherapeutics.com

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the safety and efficacy of an adipose-derived allogeneic MSC product in patients with COVID-19 and in respiratory distress; the clinical testing of an adipose-derived allogeneic MSC product; the expected enrollment of the Phase 1 trial; the potential commencement of any future clinical trials for an adipose-derived allogeneic MSC product; the ability of an adipose-derived allogeneic MSC product to work as a stand-alone therapy or in synergy with our other product candidates; the ability of an adipose-derived allogeneic MSC product to support healing and reduce the long-term effects associated with pulmonary tissue damage for COVID-19 patients; our ability to provide a supportive therapy for COVID-19 patents using an adipose-derived allogeneic MSC product; the ability of an adipose-derived allogeneic MSC product to potentially save lives of COVID-19 patients and to potentially minimize the long-term effects of COVID-19; our ability to cover all stages of the continuum of care for COVID-19; and our potential position in the antiviral industry. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's and its subsidiaries', affiliates’ and partners’ technologies and prospects and collaborations with partners, including, but not limited to risks related to seeking regulatory approval for any adipose-derived allogeneic MSC product; clinical development risks, including risks in the progress, timing, cost, and results of clinical trials and product development programs; risk of difficulties or delays in obtaining regulatory approvals; risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval; risks that prior test, study and trial results may not be replicated in future studies and trials; risks of manufacturing and supplying drug product; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist Sorrento in the execution of its COVID-19 therapeutic product candidate strategies; risks related to the global impact of COVID-19; and other risks that are described in Sorrento's most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year ended December 31, 2019, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Media and Investor Relations

Contact: Alexis Nahama, DVM (SVP Corporate Development)
ancaoli liked last!


Deelnemen aan het forum + meer functies?

Deel kennis en vragen met duizenden beleggers,
minder advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen. Registreer binnen 1 minuut!



Plaats reactie